Thiamphenicol

Producers shown on SFDA

(Record date:26/10/2021）

Producers shown on EP

Not showing any

Producer:Jiangsu Hansyn Pharmaceutical Co., Ltd. was established in 2002. Its products involve florfenicol, thiamphenicol and related products. Hengsheng pharmaceutical is the world's largest production base of florfenicol and Thiamphenicol APIs, and has industry-leading R & D, production and processing technology in the field of API molecular coating.

Staff size:200-299 people

Registered capital:RMB 120 million

Producer:Zhejiang Runkang Pharmaceutical Co., Ltd. is a comprehensive enterprise producing pharmaceutical preparations, APIs, veterinary APIs and intermediates.

The leading products of Zhejiang runkang Pharmaceutical Co., Ltd. include methylsulfonomycin, florfenicol, ciprofloxacin hydrochloride and other veterinary drug raw materials. The annual output is more than 1 billion tablets and capsules, and more than 1000 tons of various APIs. At present, 38 products have passed GMP certification.

Staff size:About 50 people

Registered capital:RMB 31.8 million

Producer:Zhejiang Kangmu Pharmaceutical Co., Ltd. (Group) was founded in 2003.

The company covers an area of 93.55 Mu and a plant construction area of 32000 square meters. It is a modern enterprise producing flufenicol and tilmicosin series raw materials. The company's products have passed the GMP certification of the Ministry of agriculture and obtained the production license and approval number.

Staff size:200-299 people
Registered capital:RMB 23 million

Producer:An'hui Liberty Pharmaceutical Co., Ltd.,was established in 2008,   The company covers an area of 140000 square meters. The production plant is designed and constructed in accordance with the requirements of FDA, egmp and GMP, adopts domestic and foreign advanced production equipment and testing instruments, and has established a strict and efficient quality management assurance system. The annual production capacity of API is 1000 tons.
Staff size:300-399 people

Registered capital:USD15 million